Company intelligence / Profile preview

Peloton Therapeutics, Inc.

Dallas, Texas, United Statespelotontherapeutics.com ↗

Ownership: Private
Employees: ~64
Development stage: Other

Overview

Peloton’s lead candidate PT2977 demonstrated a partial response rate of 24% and an overall clinical benefit rate of 78% in previously treated mRCC patients. At a median follow-up of about ten months, progression-free survival probability was approximately 50%. The company also had ongoing studies combining PT2977 with cabozantinib and exploring use in glioblastoma. A second compound, PT2567, was being developed preclinically for non-oncology indications such as PAH

Therapeutic areas: OncologyCardiovascular
Modalities: Small molecules (notably oral HIF‑2α inhibitors)
Industry: Biotech

Partnerships

Collaboration with Exelixis on combination trials with cabozantinib

Beyond the preview

Go deeper on Peloton Therapeutics, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Peloton Therapeutics, Inc..